Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes

Nature Medicine

Volumn 19, Issue 9, 2013, Pages 1132-1140

  Jourdan, Tony ^a   Godlewski, Grzegorz ^a   Cinar, Resat ^a   Bertola, Adeline ^a   Szanda, Gergo ^a   Liu, Jie ^a   Tam, Joseph ^a   Han, Tiffany ^a   Mukhopadhyay, Bani ^a   Skarulis, Monica C ^b   Ju, Cynthia ^c   Aouadi, Myriam ^d   Czech, Michael P ^d   Kunos, George ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CRYOPYRIN; GLUCOSE; HEMOGLOBIN A1C; INFLAMMASOME; INSULIN; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL LOSS; CONTROLLED STUDY; CYTOKINE RELEASE; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERINSULINEMIA; IN VITRO STUDY; INSULIN RELEASE; MACROPHAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; WILD TYPE; ZUCKER DIABETIC FATTY RAT;

ANIMALS; APOPTOSIS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; CARRIER PROTEINS; CELL LINE; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; ENDOCANNABINOIDS; HUMANS; HYPERGLYCEMIA; INFLAMMASOMES; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; POLYUNSATURATED ALKAMIDES; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

MUS; RATTUS; RODENTIA;

EID: 84883784100     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3265     Document Type: Article

References (71)

1. Defronzo, R.A. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773-795 (2009).
2. Shoelson, S.E., Lee, J. & Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801 (2006). (Pubitemid 44033299)
3. Ehses, J.A. et al. Increased number of islet-Associated macrophages in type 2 diabetes. Diabetes 56, 2356-2370 (2007). (Pubitemid 47358243)
4. Masters, S.L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1ß in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
5. Youm, Y.H. et al. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-Induced pancreatic damage. Endocrinology 152, 4039-4045 (2011).
6. Goossens, G.H. et al. Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol. Immunol. 50, 142-149 (2012).
7. Lee, H.M. et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62, 194-204 (2013).
8. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389-462 (2006). (Pubitemid 44394908)
9. Di Marzo, V. et al. Leptin-Regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825 (2001). (Pubitemid 32303781)
10. Cota, D. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423-431 (2003). (Pubitemid 38063771)
11. Osei-Hyiaman, D. et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-Induced obesity. J. Clin. Invest. 115, 1298-1305 (2005). (Pubitemid 40629049)
12. Jourdan, T. et al. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: Evidence from cultured explants. Hepatology 55, 790-799 (2012).
13. Eckardt, K. et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 52, 664-674 (2009).
14. Liu, J. et al. Hepatic cannabinoid receptor-1 mediates diet-Induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 142, 1218-1228 (2012).
15. Matias, I. et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-Pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91, 3171-3180 (2006). (Pubitemid 44271774)
16. Ravinet Trillou, C. et al. Anti-Obesity effect of SR141716, a CB1 receptor antagonist, in diet-Induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R345-R353 (2003).
17. Jourdan, T. et al. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-Induced obese mice. Diabetes 59, 926-934 (2010).
18. Després, J.P., Golay, A. & Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121-2134 (2005). (Pubitemid 41653104)
19. Addy, C. et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 7, 68-78 (2008).
20. Rosenstock, J., Hollander, P., Chevalier, S. & Iranmanesh, A. SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31, 2169-2176 (2008).
21. Le Foll, B., Gorelick, D.A. & Goldberg, S.R. The future of endocannabinoid-Oriented clinical research after CB1 antagonists. Psychopharmacology (Berl.) 205, 171-174 (2009).
22. Tam, J. et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 120, 2953-2966 (2010).
23. Tam, J. et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 16, 167-179 (2012).
24. Jetton, T.L. et al. Mechanisms of compensatory beta-Cell growth in insulin-Resistant rats: Roles of Akt kinase. Diabetes 54, 2294-2304 (2005). (Pubitemid 41134255)
25. Topp, B.G., Atkinson, L.L. & Finegood, D.T. Dynamics of insulin sensitivity,-Cell function, and-Cell mass during the development of diabetes in fa/fa rats. Am. J. Physiol. Endocrinol. Metab. 293, E1730-E1735 (2007). (Pubitemid 350255126)
26. Rohrbach, K. et al. Ibipinabant attenuates beta-Cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes. Metab. 14, 555-564 (2012).
27. Kim, W. et al. Cannabinoids induce pancreatic beta-Cell death by directly inhibiting insulin receptor activation. Sci. Signal. 5, ra23 (2012).
28. Oslowski, C.M. et al. Thioredoxin-Interacting protein mediates ER stress-Induced beta cell death through initiation of the inflammasome. Cell Metab. 16, 265-273 (2012).
29. Lerner, A.G. et al. IRE1alpha induces thioredoxin-Interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab. 16, 250-264 (2012).
30. Han, K.H. et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc. Res. 84, 378-386 (2009).
31. Osundiji, M.A. et al. Brain glucose sensors play a significant role in the regulation of pancreatic glucose-Stimulated insulin secretion. Diabetes 61, 321-328 (2012).
32. Calegari, V.C. et al. Inflammation of the hypothalamus leads to defective pancreatic islet function. J. Biol. Chem. 286, 12870-12880 (2011).
33. O?Hare, J.D., Zielinski, E., Cheng, B., Scherer, T. & Buettner, C. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes 60, 1055-1062 (2011).
34. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-Interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140 (2010).
35. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
36. Wolf, A.M., Wolf, D., Rumpold, H., Enrich, B. & Tilg, H. Adiponectin induces the anti-Inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 323, 630-635 (2004). (Pubitemid 39221142)
37. Kharroubi, I., Rasschaert, J., Eizirik, D.L. & Cnop, M. Expression of adiponectin receptors in pancreatic beta cells. Biochem. Biophys. Res. Commun. 312, 1118-1122 (2003). (Pubitemid 37490931)
38. Baldwin, W. et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60, 1258-1269 (2011).
39. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-Associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006). (Pubitemid 43372104)
40. van Rooijen, N. & Hendrikx, E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol. Biol. 605, 189-203 (2010).
41. Aouadi, M. et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458, 1180-1184 (2009).
42. Tesz, G.J. et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem. J. 436, 351-362 (2011).
43. Kim, W. et al. Cannabinoids inhibit insulin receptor signaling in pancreatic beta-Cells. Diabetes 60, 1198-1209 (2011).
44. Stienstra, R. et al. The inflammasome-Mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593-605 (2010).
45. Dostert, C. et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008). (Pubitemid 351928351)
46. Lee, G.S. et al. The calcium-Sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492, 123-127 (2012).
47. Liu, J. et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346, 835-840 (2000). (Pubitemid 30171048)
48. Han, M.S. et al. JNK expression by macrophages promotes obesity-Induced insulin resistance and inflammation. Science 339, 218-222 (2013).
49. Starowicz, K.M. et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-Fat diet. Obesity (Silver Spring) 16, 553-565 (2008). (Pubitemid 351328005)
50. Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316, 977-984 (1996).
51. Varga, K., Wagner, J.A., Bridgen, D.T. & Kunos, G. Platelet-And macrophage-Derived endogenous cannabinoids are involved in endotoxin-Induced hypotension. FASEB J. 12, 1035-1044 (1998). (Pubitemid 28359585)
52. Vilches-Flores, A., Hauge-Evans, A.C., Jones, P.M. & Persaud, S.J. Chronic activation of cannabinoid receptors in vitro does not compromise mouse islet function. Clin. Sci. (Lond.) 127, 467-478 (2013).
53. Larsen, C.M. et al. Interleukin-1-Receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007). (Pubitemid 46588416)
54. Mukhopadhyay, B. et al. Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-γ. J. Biol. Chem. 285, 19002-19011 (2010).
55. Geurts, L., Muccioli, G.G., Delzenne, N.M. & Cani, P.D. Chronic endocannabinoid system stimulation induces muscle macrophage and lipid accumulation in type 2 diabetic mice independently of metabolic endotoxaemia. PLoS ONE 8, e55963 (2013).
56. Grapov, D., Adams, S.H., Pedersen, T.L., Garvey, W.T. & Newman, J.W. Type 2 diabetes associated changes in the plasma non-Esterified fatty acids, oxylipins and endocannabinoids. PLoS ONE 7, e48852 (2012).
57. Mehran, A.E. et al. Hyperinsulinemia drives diet-Induced obesity independently of brain insulin production. Cell Metab. 16, 723-737 (2012).
58. Tang, Y. et al. Beneficial metabolic effects of CB1R anti-Sense oligonucleotide treatment in diet-Induced obese AKR/J mice. PLoS ONE 7, e42134 (2012).
59. Maedler, K. et al. Glucose-Induced beta cell production of IL-1ß contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851-860 (2002).
60. Louvet, A. et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 54, 1217-1226 (2011).
61. Wang, L., Liu, J., Harvey-White, J., Zimmer, A. & Kunos, G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-Dependent decline in mice. Proc. Natl. Acad. Sci. USA 100, 1393-1398 (2003). (Pubitemid 36184012)
62. Chorvat, R.J., Berbaum, J., Seriacki, K. & McElroy, J.F. JD-5006 and JD-5037: Peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg. Med. Chem. Lett. 22, 6173-6180 (2012).
63. Folch, J., Lees, M. & Sloane Stanley, G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497-509 (1957).
64. Godlewski, G. et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem. Biol. 17, 1256-1266 (2010).
65. Mukhopadhyay, B. et al. Hyperactivation of anandamide synthesis and regulation of cell-Cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc. Natl. Acad. Sci. USA 108, 6323-6328 (2011).
66. Buettner, C. et al. Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. J. Clin. Invest. 115, 1306-1313 (2005). (Pubitemid 40629050)
67. Ju, C. & Pohl, L.R. Immunohistochemical detection of protein adducts of 2,4-Dinitrochlorobenzene in antigen presenting cells and lymphocytes after oral administration to mice: Lack of a role of Kupffer cells in oral tolerance. Chem. Res. Toxicol. 14, 1209-1217 (2001). (Pubitemid 32911459)
68. Tesz, G.J. et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem. J. 436, 351-362 (2011).
69. Rosen, E.D. et al. Targeted elimination of peroxisome proliferator-Activated receptor γ in ß cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol. Cell Biol. 23, 7222-7229 (2003). (Pubitemid 37214026)
70. Liu, J. et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-Kinase/NF-kB independently of platelet-Activating factor. J. Biol. Chem. 278, 45034-45039 (2003). (Pubitemid 37377264)
71. Varga, K., Wagner, J.A., Bridgen, D.T. & Kunos, G. Platelet-And macrophage-Derived endogenous cannabinoids are involved in endotoxin-Induced hypotension. FASEB J. 12, 1035-1044 (1998). (Pubitemid 28359585)